MESO
$14.93
Mesoblast Ltd Ads
($.35)
(2.29%)
MESO
Earnings Whisper ®
N/A
2nd Quarter December 2020
Consensus:  ($0.08)
Revenue:  $27.14 Mil
Thursday
Feb 18
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when MESO reports earnings?
Beat
Meet
Miss

Where is MESO's stock price going from here?
Up
Flat
Down
Stock chart of MESO
Analysts
Summary of analysts' recommendations for MESO
Score
Grade
Pivots
Resistance
$15.84
$15.61
$15.27

$15.04

Support
$14.70
$14.47
$14.13
Tweet
Growth
Description
Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.